The brokerage downplayed concerns over Eli Lilly’s oral GLP-1 candidate Orforglipron and generic risks to Novartis’ heart drug Entresto, which contributes about 20% of Divi’s consolidated revenue. It expects Divi’s to remain a key API supplier, supported by a healthy order pipeline and rising demand in peptides, making the recent stock weakness a buying opportunity.
Over the past month, the stock has fallen 7.08% compared with a 0.84% decline in the Sensex.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit rose 26.74% to Rs 545 crore while net sales rose 13.79% to Rs 2410 crore in Q1 June 2025 over Q1 June 2024.